475 articles with MorphoSys AG
MorphoSys AG and Incyte Corporation have inked a collaboration and license deal to further develop and commercialize MorphoSys’ anti-CD19 antibody tafasitamab around the world.
MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tafasitamab, an anti-CD19 antibody, for the treatment of relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL).
The primary endpoint is the incidence and severity of treatment-emergent adverse events, key secondary endpoints are objective response rate and PET-negative complete response rate at the end of treatment.
11/22/2019Pharma and biotech companies strengthen their leadership teams and boards with this week's appointments.
MorphoSys AG announced that Dr. Markus Enzelberger, the company's Chief Scientific Officer, has decided to step down as CSO and member of the company's Management Board to explore new opportunities. Dr. Enzelberger will leave MorphoSys on February 29, 2020.
MorphoSys announced that the ongoing tafasitamab phase 3 B-MIND study has successfully passed the pre-planned, event-driven interim analysis for futility.
MorphoSys announced the opening of its new U.S. headoffice. Based in Boston, MA, one of the world's leading innovation and biotech hubs, the new location will enable MorphoSys to establish and expand its U.S.
MorphoSys AG announced that its licensee Novartis presented phase 2 results for bimagrumab, a human anti-activin receptor monoclonal antibody developed by Novartis and generated utilizing MorphoSys's proprietary HuCAL antibody technology.
MorphoSys AG announced presentation of so far unpublished data on tafasitamab, its proprietary key asset and investigational hemato-oncological drug candidate, at the upcoming 61th American Society of Hematology 2019 Annual Meeting, taking place from December 7-10, 2019 in Orlando, Florida.
11/4/2019Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone
MorphoSys AG announced topline results from the primary analysis of the retrospective observational matched control cohort This study was designed to compare the effectiveness of lenalidomide monotherapy based on real-world patient data with the efficacy outcomes of the tafasitamab/lenalidomide combination, as investigated in MorphoSys's L-MIND trial
MorphoSys AG announced the end of the clinical development program of MOR106 in atopic dermatitis.
MorphoSys AG reported its financial results for the third quarter of 2019.
The companies indicate that the decision was based on lack of efficacy, not any safety concerns.
MorphoSys AG will publish its first nine months' 2019 results on October 29, 2019 at 10:00pm CET
I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China
I-Mab Biopharma and MorphoSys AG announced that I-Mab has received Investigational New Drug clearances from the National Medical Products Administration of China to expand the ongoing phase II and III clinical trials of TJ202/MOR202, MorphoSys's human monoclonal anti-CD38 antibody for the treatment of multiple myeloma, also to mainland China.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
MorphoSys AG will present at the following conferences
MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC issued a press release to report the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval of Tremfya for the treatment of adult patients with active psoriatic arthritis.
MorphoSys Announces Intention to Submit Marketing Authorization Application for Tafasitamab to European Medicines Agency
MorphoSys AG announced its intention to submit a Marketing Authorization Application to the European Medicines Agency based on its phase 2 L-MIND study of tafasitamab and lenalidomide in relapsed or refractory diffuse large B cell lymphoma.